Noninvasive Detection of Slow Conduction with Cardiac Magnetic Resonance Imaging for VT Ablation.

Ventricular tachycardia ablation cardiac magnetic resonance conducting channels deceleration zones isochronal late activation maps

Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
23 Jan 2024
Historique:
received: 27 11 2023
accepted: 11 01 2024
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

Noninvasive myocardial scar characterization with cardiac magnetic resonance (CMR) has been shown to accurately identify conduction channels and can be an important aid for ventricular tachycardia (VT) ablation. A new mapping method based on targeting deceleration zones (DZs) has become one of the most commonly used strategies for VT ablation procedures. To analyze the capability of CMR to identify DZs and to find predictors of arrhythmogenicity in CMR channels. Forty-four consecutive patients with structural heart disease and VT undergoing ablation after CMR at a single center (October 2018 to July 2021) were included (mean age, 64.8±11.6 years; 95.5% male; 70.5% with ischemic heart disease; mean ejection fraction of 32.3±7.8%). Characteristics of CMR channels were analyzed, and correlations with DZs detected during isochronal late activation mapping (ILAM) in both baseline maps and remaps were determined. Overall, 109 automatically detected CMR channels were analyzed (2.48±1.15 per patient; length, 57.91±63.07 mm; CC mass, 2.06±2.67 grams; protectedness, 21.44±25.39 mm). Overall, 76.1% of CMR channels were associated with a DZ. Univariate analysis showed that channels associated with DZs were longer (67.81±68.45 vs. 26.31±21.25 mm, OR 1.03, p=0.010), with higher border zone mass (2.41±2.91 vs. 0.87±0.86 g, OR 2.46, p=0.011) and greater protectedness (24.97±27.72 vs. 10.19±9.52 mm, OR 1.08, p=0.021). Noninvasive detection of targets for VT ablation is possible with CMR. DZs found during EAM accurately correlate with CMR channels, especially those with increased length, border zone mass and protectedness.

Sections du résumé

BACKGROUND BACKGROUND
Noninvasive myocardial scar characterization with cardiac magnetic resonance (CMR) has been shown to accurately identify conduction channels and can be an important aid for ventricular tachycardia (VT) ablation. A new mapping method based on targeting deceleration zones (DZs) has become one of the most commonly used strategies for VT ablation procedures.
AIMS OBJECTIVE
To analyze the capability of CMR to identify DZs and to find predictors of arrhythmogenicity in CMR channels.
METHODS METHODS
Forty-four consecutive patients with structural heart disease and VT undergoing ablation after CMR at a single center (October 2018 to July 2021) were included (mean age, 64.8±11.6 years; 95.5% male; 70.5% with ischemic heart disease; mean ejection fraction of 32.3±7.8%). Characteristics of CMR channels were analyzed, and correlations with DZs detected during isochronal late activation mapping (ILAM) in both baseline maps and remaps were determined.
RESULTS RESULTS
Overall, 109 automatically detected CMR channels were analyzed (2.48±1.15 per patient; length, 57.91±63.07 mm; CC mass, 2.06±2.67 grams; protectedness, 21.44±25.39 mm). Overall, 76.1% of CMR channels were associated with a DZ. Univariate analysis showed that channels associated with DZs were longer (67.81±68.45 vs. 26.31±21.25 mm, OR 1.03, p=0.010), with higher border zone mass (2.41±2.91 vs. 0.87±0.86 g, OR 2.46, p=0.011) and greater protectedness (24.97±27.72 vs. 10.19±9.52 mm, OR 1.08, p=0.021).
CONCLUSIONS CONCLUSIONS
Noninvasive detection of targets for VT ablation is possible with CMR. DZs found during EAM accurately correlate with CMR channels, especially those with increased length, border zone mass and protectedness.

Identifiants

pubmed: 38262674
pii: 7585837
doi: 10.1093/europace/euae025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Sara Vázquez-Calvo (S)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Judit Mas Casanovas (J)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.

Paz Garre (P)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Paula Sánchez-Somonte (P)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Pasquale Valerio Falzone (PV)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Laura Uribe (L)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Eduard Guasch (E)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

José Maria Tolosana (JM)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Roger Borras (R)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red e Salud Mental, CIBERSAM, Instituto de Salud Carlos III.

Elena Arbelo (E)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

José T Ortiz-Pérez (JT)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Susana Prats (S)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Rosario J Perea (RJ)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Josep Brugada (J)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Lluís Mont (L)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Andreu Porta-Sanchez (A)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Ivo Roca-Luque (I)

Institut Clinic Cardiovascular, Hospital Clínic, Universitat de Barcelona. Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Centro de Investigación Biomédica en Red, Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Classifications MeSH